Skip to main content

Table 2 Adverse events

From: Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study

NCI-CTC grade (ver.5) CBDCA + GEM (n = 65) CDDP + VNR (n = 17)  
G1/2 (%) G3/4 (%) total G1/G2 (%) G3/4 (%) total P
Hematological event
 White blood cell decreased 21 (32.3) 0 21 (32.3) 6 (35.2) 0 6 (35.2) 0.925
 Neutropenia 18 (27.6) 10 (15.3) 28 (43.0) 3 (17.6) 8(47.0) 11 (64.7) 0.002*
 Thrombocytopenia 21 (32.2) 3 (4.6) 24 (36.9) 2 (11.7) 0 2 (11.7) 0.377
 Anemia 5 (7.6) 0 5 (7.6) 1 (5.8) 0 1 (5.8) 0.076
 Febrile neutropenia 0 0 0 0 0 0  
Non-hematological event
 Nausea 5 (7.6) 0 5 (7.6) 10 (58.8) 2(11.7) 1 2(70.5) < 0.001*
 Anorexia 5 (7.6) 0 5 (7.6) 6 (35.2) 3(17.6) 9 (52.9) < 0.001*
 Mucositis oral 2 (3.0) 0 2 (3.0) 0 0 0 0.464
 Fatigue 7 (10.7) 0 7 (10.7) 7 (41.1) 0 7 (41.1) 0.045*
 AST increased 5 (7.6) 0 5 (7.6) 1 (5.8) 0 1 (5.8) 0.798
 ALT increased 10 (15.3) 0 10 (15.3) 3 (17.6) 0 3 (17.6) 0.272
 Creatinine increased 2 (3.0) 0 2 (3.0) 2 (11.7) 0 2 (11.7) 0.121
 Constipation 14 (21.5) 0 14 (21.5) 2 (11.7) 0 2 (11.7) 0.631
 Diarrhea 1 (1.5) 0 1 (1.5) 0 0 0 0.606
 Pneumonitis 1 (1.5) 0 1 (1.5) 0 1(5.8) 1 (5.8) 0.128
 Infection 1 (1.5) 0 1 (1.5) 0 0 0 0.606
 Rash 3 (4.6) 0 3 (4.6) 0 0 0 0.665
 Hypophosphatemia 1 (1.5) 0 1 (1.5) 0 0 0 0.606
 Vertigo 2 (3.0) 0 2 (3.0) 1 (5.8) 0 1 (5.8) 0.583
 Insomnia 1 (1.5) 0 1 (1.5) 0 0 0 0.606
 Alopecia 1 (1.5) 0 1 (1.5) 0 0 0 0.606
 Peripheral nerve disorder 1 (1.5) 0 1 (1.5) 0 0 0 0.606
 Supraventricular tachycardia 0 1 (1.5) 1 (1.5) 0 0 0 0.606
 Vasculitis 0 0 0 5 (29.4) 0 5 (29.4) < 0.001*
  1. *P < 0.05